SanofiMEX:SAN1N 72 ROE % is 5.58% as of Dec. 2025, which is 35% below its 10-year median of 8.61. GuruFocus rates MEX:SAN1N with a GF Score™ of 72/100 and a GF Value™ of MXN2,212.65 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 936 Drug Manufacturers companies, Sanofi ranks better than 66.99% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sanofi's annualized net income for the quarter that ended in Dec. 2025 was MXN84,378 Mil. Sanofi's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was MXN1,512,649 Mil. Therefore, Sanofi's annualized ROE % for the quarter that ended in Dec. 2025 was 5.58%.
The historical rank and industry rank for Sanofi's ROE % or its related term are showing as below:
MEX:SAN1N'
s ROE % Range Over the Past 10 Years
Min: 4.67 Med: 8.61 Max: 19.25
Current: 10.71
During the past 13 years, Sanofi's highest ROE % was 19.25%. The lowest was 4.67%. And the median was 8.61%.
MEX:SAN1N's ROE % is ranked better than 66.99% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs MEX:SAN1N: 10.71
Sanofi (MEX:SAN1N) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Sanofi ROE % Related Terms
Sanofi ROE % Historical Data
* Premium members only.
The historical data trend for Sanofi's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Sanofi's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's ROE % distribution charts can be found below:
* The bar in red indicates where Sanofi's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Sanofi (MEX:SAN1N) has a ROE % of 5.58% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sanofi and its competitors. This is 35% below median its historical median of 8.61. Over the past decade, Sanofi's ROE % has ranged from 4.67 to 19.25. According to the industry distribution chart, Sanofi ranks #309 out of 936 companies in the Drug Manufacturers industry, placing it in the top 33%.
Is Sanofi's ROE % too high?
Sanofi's current ROE % of 5.58% is 35% below median its 10-year median of 8.61. Over the past 10 years, this metric has ranged from a low of 4.67 to a high of 19.25. The Drug Manufacturers industry median ROE % is 5.87. Sanofi's value of 5.58% is 4.9% below this industry median. Based on the distribution chart, Sanofi ranks #309 out of 936 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sanofi has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #309 out of 936 companies for ROE %. This puts Sanofi in the upper half of its industry. The industry median ROE % is 5.87. Sanofi's value of 5.58% is 4.9% below this benchmark. Historically, Sanofi's own ROE % has ranged from 4.67 to 19.25 over the past decade. While the company's 10-year median is 8.61 vs. the industry median of 5.87, Sanofi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi's current ROE % of 5.58% is 4.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sanofi and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current ROE % is 5.58%, which is 35% below median its own 10-year median of 8.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (MEX:SAN1N) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,212.65, compared to a current price of MXN1,525.85 — trading 31% below its estimated fair value. The current ROE % is 5.58%, which is 35% below median its 10-year median of 8.61 and 4.9% below the Drug Manufacturers industry median of 5.87. Sanofi's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Sanofi (MEX:SAN1N), the current ROE % is 5.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (MEX:SAN1N) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of MXN1,525.85 is trading 31% below its estimated GF Value™ of MXN2,212.65.
GuruFocus considers Sanofi to be Possible Value Trap.
Key valuation signals for MEX:SAN1N:
ROE %: 5.58% (35% below median its 10-year median of 8.61)
GF Value™: MXN2,212.65 vs. price of MXN1,525.85 (31% below fair value)
Industry Position: 4.9% below the Drug Manufacturers median (#309 of 936)
No single metric tells the full story. See the MEX:SAN1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
72GF Score
Get the complete analysis for MEX:SAN1N
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SAN1N has been successfully added to your 
